Gollapudi B Bhaskar, Lynch Anthony M, Heflich Robert H, Dertinger Stephen D, Dobrovolsky Vasily N, Froetschl Roland, Horibata Katsuyoshi, Kenyon Michelle O, Kimoto Takafumi, Lovell David P, Stankowski Leon F, White Paul A, Witt Kristine L, Tanir Jennifer Y
E(x)ponent , Midland, MI, USA.
GlaxoSmithKline, Hertfordshire, UK.
Mutat Res Genet Toxicol Environ Mutagen. 2015 May 1;783:23-35. doi: 10.1016/j.mrgentox.2014.09.007. Epub 2014 Sep 26.
The in vivo Pig-a assay uses flow cytometry to measure phenotypic variants for antibody binding to cell surface glycosylphosphatidylinositol (GPI)-anchored proteins. There is good evidence suggesting that the absence of antibody binding is the result of a mutation in the endogenous X-linked Pig-a gene, which forms the rationale for the assay. Although the assay has been performed with several types of hematopoietic cells and in a variety of mammalian species, including humans, currently it is optimized only for measuring CD59-deficient (presumed Pig-a mutant) erythrocytes in the peripheral blood of rats. An expert workgroup formed by the International Workshop on Genotoxicity Testing considered the state of assay development and the potential of the assay for regulatory use. Consensus was reached on what is known about the Pig-a assay and how it should be conducted, and recommendations were made on additional data and refinements that would help to further enhance the assay for use in hazard identification and risk assessment.
体内Pig-a检测采用流式细胞术来测量抗体与细胞表面糖基磷脂酰肌醇（GPI）锚定蛋白结合的表型变异体。有充分证据表明，抗体结合缺失是内源性X连锁Pig-a基因突变的结果，这构成了该检测方法的理论基础。尽管该检测已在多种类型的造血细胞以及包括人类在内的多种哺乳动物物种中进行，但目前仅针对测量大鼠外周血中CD59缺陷型（假定为Pig-a突变体）红细胞进行了优化。遗传毒性检测国际研讨会成立的一个专家工作组审议了该检测方法的发展状况及其用于监管的潜力。就Pig-a检测已知的内容以及应如何进行该检测达成了共识，并就有助于进一步改进该检测以用于危害识别和风险评估的其他数据及改进措施提出了建议。
